{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T07:52:52Z","timestamp":1682409172675},"reference-count":21,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2022,1,29]]},"DOI":"10.1536\/ihj.21-396","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T22:10:29Z","timestamp":1643407829000},"page":"85-90","source":"Crossref","is-referenced-by-count":1,"title":["Suitable Dose of Long-Term Tolvaptan to Reduce Heart Failure Rehospitalizations"],"prefix":"10.1536","volume":"63","author":[{"given":"Masami","family":"Nishino","sequence":"first","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shodai","family":"Kawanami","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Sugae","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Ukita","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akito","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Matsuhiro","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Yasumoto","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotaka","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuharu","family":"Matsunaga-Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Yano","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Egami","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Tanouchi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ambrosy AP, Pang PS, Khan S, <i>et al<\/i>. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the Everest trial. Eur Heart J 2013; 34: 835-43.","DOI":"10.1093\/eurheartj\/ehs444"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Singh D, Shrestha K, Testani JM, <i>et al<\/i>. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail 2014; 20: 392-9.","DOI":"10.1016\/j.cardfail.2014.03.006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Dini FL, Ghio S, Klersy C, <i>et al<\/i>. Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis. Int J Clin Pract 2013; 67: 656-64.","DOI":"10.1111\/ijcp.12144"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Miura M, Sugimura K, Sakata Y, <i>et al<\/i>. Prognostic impact of loop diuretics in patients with chronic heart failure - effects of addition of renin-angiotensin-aldosterone system inhibitors and \u03b2-blockers. Circ J 2016; 80: 1396-403.","DOI":"10.1253\/circj.CJ-16-0216"},{"key":"5","unstructured":"5. Yamamura Y, Nakamura S, Itoh S, <i>et al<\/i>. Opc-41061, a highly potent human vasopressin v2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-7."},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Gheorghiade M, Konstam MA, Burnett JC, <i>et al<\/i>. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the Everest clinical status trials. JAMA 2007; 297: 1332-43.","DOI":"10.1001\/jama.297.12.1332"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Felker GM, Mentz RJ, Cole RT, <i>et al<\/i>. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol 2017; 69: 1399-406.","DOI":"10.1016\/j.jacc.2016.09.004"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Konstam MA, Kiernan M, Chandler A, <i>et al<\/i>. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol 2017; 69: 1409-19.","DOI":"10.1016\/j.jacc.2016.12.035"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kinugawa K, Sato N, Inomata T. Effects of tolvaptan on volume overload in patients with heart failure. Int Heart J 2018; 59: 1368-77.","DOI":"10.1536\/ihj.18-119"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Felker GM, Lee KL, Bull DA, <i>et al<\/i>. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797-805.","DOI":"10.1056\/NEJMoa1005419"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56: 1527-34.","DOI":"10.1016\/j.jacc.2010.06.034"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Inomata T, Ikeda Y, Kida K, <i>et al<\/i>. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment - results from the k-star study. Circ J 2017; 82: 159-67.","DOI":"10.1253\/circj.CJ-17-0179"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, <i>et al<\/i>. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the japanese cardiac registry of heart failure in cardiology (jcare-card). Circ J 2009; 73: 1893-900.","DOI":"10.1253\/circj.CJ-09-0254"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sato N, Kajimoto K, Keida T, <i>et al<\/i>. Clinical features and outcome in hospitalized heart failure in japan (from the attend registry). Circ J 2013; 77: 944-51.","DOI":"10.1253\/circj.CJ-13-0187"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shirakabe A, Hata N, Yamamoto M, <i>et al<\/i>. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J 2014; 78: 911-21.","DOI":"10.1253\/circj.CJ-13-1255"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Jujo K, Saito K, Ishida I, <i>et al<\/i>. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 2016; 3: 177-88.","DOI":"10.1002\/ehf2.12088"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Matsue Y, Suzuki M, Torii S, <i>et al<\/i>. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 2016; 22: 423-32.","DOI":"10.1016\/j.cardfail.2016.02.007"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Solomon SD, Dobson J, Pocock S, <i>et al<\/i>. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116: 1482-7.","DOI":"10.1161\/CIRCULATIONAHA.107.696906"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Bello NA, Claggett B, Desai AS, <i>et al<\/i>. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circ Heart Fail 2014; 7: 590-5.","DOI":"10.1161\/CIRCHEARTFAILURE.113.001281"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Peri-Okonny PA, Mi X, Khariton Y, <i>et al<\/i>. Target doses of heart failure medical therapy and blood pressure: Insights from the champ-hf registry. JACC Heart Fail 2019; 7: 350-8.","DOI":"10.1016\/j.jchf.2018.11.011"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Bozkurt B. Reasons for lack of improvement in treatment with evidence-based therapies in heart failure. J Am Coll Cardiol 2019; 73: 2384-7.","DOI":"10.1016\/j.jacc.2019.03.464"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/1\/63_21-396\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T03:43:05Z","timestamp":1643427785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/63\/1\/63_21-396\/_article"}},"subtitle":["AURORA Study"],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.21-396","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"article-number":"21-396"}}